CTOs on the Move

Medrobotics

www.medrobotics.com

 
Medrobotics Corporation manufactures and markets the Flex® System, a robot-assisted platform that provides single-site access and visualization of hard-to-reach anatomical locations and the Flex® Retractor, a low profile, fully adjustable transoral retractor that accommodates advanced surgical systems.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Medrobotics raised $25M on 11/07/2015
Medrobotics raised $20M on 01/27/2017

Similar Companies

EBD Group

EBD Group, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

South County Hospital

South County Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. South County Hospital is based in Wakefield, RI. You can find more information on South County Hospital at www.schospital.com

VisuWell

VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.

Ryogen

Ryogen is a Suffern, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.